Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy

NCT01094548 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: Tecemotide (L-BLP25)
BIOLOGICAL: Tecemotide (L-BLP25)
DRUG: Single low dose cyclophosphamide
DRUG: Multiple low dose cyclophosphamide

Sponsor

Merck KGaA, Darmstadt, Germany